ClinicalTrials.gg
TerminatedNCT04428775Updated Nov 8, 2021

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

A Phase 2 interventional study of ALZT-OP1a (cromolyn) in Amyotrophic Lateral Sclerosis, sponsored by AZTherapies, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-08.

Sponsored by AZTherapies, Inc. · Phase 2, Interventional, and Basic science

Why this study was terminated
Low enrollment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
238th of 307
12 · median 33
Started
2020
with 28 others
Phase 2
89 of 440
8 open now
Registered
267th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 238th largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 89 in phase 2, and was the 267th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase IIa, randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The protocol is designed to determine whether ALZT-OP1a treatment will positively impact neuro-inflammatory biomarkers and slow down or arrest functional decline in subjects with mild to moderate ALS.

Read the detailed description

This Phase IIa study is designed as a randomized, open-label, multi-center, multi-dose study for subjects with mild to moderate ALS. The study will evaluate 1) safety, 2) tolerability, 3) changes in physical function measured using the ALSFRS-R, 4) two doses of ALZT-OP1a in order to determine an optimal and effective dose that could positively impact neuro-inflammatory biomarkers, and 5) to demonstrate preliminary evidence if this treatment could potentially slow down or arrest functional decline in subjects with mild to moderate ALS.

Up to 80 evaluable subjects will be randomly assigned to one of two treatment groups: Group I (n=40) will consist of low dose ALZT-OP1a, administered via dry powder inhalation; OR Group II (n=40), which will consist of high dose ALZT-OP1a, administered via dry powder inhaler.

Subjects will dose for 12 weeks and will be asked to return to the site for scheduled visits and biomarker collection at Week 4, Week 8, and Week 12.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Amyotrophic Lateral Sclerosis
  • Lou Gehrig's disease
  • mild ALS
  • moderate ALS
  • mild to moderate ALS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 18-75 years, both inclusive;
  • Must provide written before any study related procedures;
  • Should be capable to complete all trial related procedures, assessments and visits in the judgement of Investigator;
  • Familial or sporadic ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria;
  • Disease duration from ALS diagnosis ≤24 months;
  • ALSFRS-R total score ≥ 36 at screening visit;
  • ALSFRS-R Breathing sub-score should be ≥9 at the time of screening;
  • ALSFRS-R Bulbar sub-score should be ≥9 at the time of screening;
  • Peak inspiratory flow rate (PIFR) ≥ 100 L/minute;
  • Forced vital capacity (FVC) >70% of predicted value;
  • Participant must be receiving treatment with stable dose of standard of care treatment for ≥30 days prior to signing informed consent.

Exclusion criteria

Exclusion Criteria:

  • Subjects with bulbar-onset ALS;
  • Any use of non-invasive ventilation (e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation;
  • Any other significant neurological disorder which can interfere with study assessments, e.g., significant cognitive impairment and/or clinical dementia;
  • Significant psychiatric illness like schizophrenia, bipolar disorder etc. Subjects with depression can be included, only if the depression has been stable and no episode of major depression has occurred in past one year;
  • Severe cardiac disease (e.g., interval > 500ms), Torsade de Pointes, evidence of significant heart failure ( [NYHA] Class 3 or greater, myocardial infarction or unstable angina in the 6 months prior to screening);
  • Any moderate-to-severe pulmonary disease or difficulty taking inhaled drugs;
  • Inability to tolerate the administration of an oral inhaled powder via dry powder inhaler (DPI);
  • Has taken any study drug within 30 days or five half-lives of the drug, whichever is longer, prior to dosing;
  • Currently taking cromolyn, or has taken cromolyn, within the past 12 months;
  • Allergy to cromolyn or cromolyn products, such as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.;
  • Taking inhaled protein products on a chronic basis (such as insulin, parathyroid hormone [PTH], etc.);
  • Subjects who weigh 88 lb (40 kg) or less, or, (BMI) of \<17.5 or >35.0 at screening;
  • Moderate-to-severe liver disease: (AST), alanine aminotransferase (ALT), or concentrations >3 times the ; patients with hepatic diseases such as hepatic cirrhosis, hepatic cancer and active hepatitis
  • Moderate-to-severe renal disease: \<45 mL/min/1.73 m2 (by Cockcroft-Gault calculation);
  • Any disorder or laboratory abnormality that, in the investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of the study results;
  • Pregnant or breast-feeding females or sexually active females with , if no adequate measures are used.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group I (Low Dose)

    Group I (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 17.1 mg/twice a day (bid) (total of 34.2 mg/day)

    Drug: ALZT-OP1a (cromolyn)

  • Experimental
    Group II (High Dose)

    Group II (n=40) will receive treatment regimen of ALZT-OP1a (cromolyn) 34.2 mg/bid (total of 68.4 mg/day)

    Drug: ALZT-OP1a (cromolyn)

Interventions

  • 1. Mast cell stabilizer 2. Neuroinflammatory microglial modulator 3. anti-inflammatory

    Also known as: Cromolyn, Cromolyn sodium, Sodium cromoglycate

06

What researchers measure

Primary outcomes

  1. Plasma Biomarkers

    To measure the effect of ALZT-OP1a treatment on selected plasma biomarkers in ALS patients. Candidate biomarkers in ng/mL include: Beta-tryptase, Beta-Hexosaminidase Candidate biomarkers in pg/mL include: CXCL1, interferon-y, interleukin (IL)-1a, IL-1b, IL-2, IL-5, IL-6, IL-8, IL-10, IL-15, IL-17, macrophage inflammatory protein (MIP)-1a, MIP-1b, monocyte chemoattractant protein (MCP)-1, neurofilament light protein (NfL), tumor necrosis factor (TNF)-a, and vascular endothelial growth factor (VEGF)

    Time frame: up to 12 weeks

Secondary outcomes

  1. Changes from baseline in ALS disease progression

    Measured by ALS Functional Rating Scale-Revised (ALSFRS-R) - Questionnaire

    Time frame: up to 12 weeks

  2. Time to Event Requiring Respiratory Support

    Measured by the time to event requiring full-time or nearly full-time respiratory support from baseline by treatment arm.

    Time frame: up to 12 weeks

  3. Changes from baseline in pulmonary function (forced vital capacity)

    Measured by changes in forced vital capacity (FVC) in percent predicted value from baseline by treatment arm.

    Time frame: up to 12 weeks

  4. Changes from baseline in pulmonary function (peak inspiratory flow rate)

    Measured by changes in peak inspiratory flow rate (PIFR) in liters per minute from baseline by treatment arm.

    Time frame: up to 12 weeks

  5. Incidence of adverse event (tolerability) related to ALZT-OP1a

    Evaluated by number and percentage of unexpected adverse events by treatment arm.

    Time frame: up to 12 weeks

  6. Number of participants with abnormal vital signs

    Measured by changes in systolic / diastolic blood pressure, pulse rate, respiratory rate, and body temperature from baseline by treatment arm. The data will also be presented in shift tables as within normal limits, clinically significant, not clinically significant.

    Time frame: up to 12 weeks

  7. Number of participants with abnormal physical or neurological examinations

    Review of all body systems and changes evaluated for clinical significance from baseline by treatment arm. The data will also be presented in shift tables as within normal limits, clinically significant, not clinically significant.

    Time frame: up to 12 weeks

  8. Number of participants with abnormal electrocardiograms (ECGs)

    Measured by changes in heart rate, PR interval, QRS complex, and QT interval from baseline by treatment arm. The data will also be presented in shift tables as within normal limits, clinically significant, not clinically significant.

    Time frame: up to 12 weeks

  9. Number of participants with treatment emergent clinically significant laboratory assessments

    The abnormal values will be presented by treatment arm from baseline. The data will also be presented in shift tables as within normal limits, clinically significant, not clinically significant.

    Time frame: up to 12 weeks

  10. Changes from baseline in suicidal ideation and behavior

    Measured by changes in Columbia Suicide Severity Rating Scale (C-SSRS) from baseline; minimum score: 0 maximum score: 10; lower values represent a better outcome.

    Time frame: up to 12 weeks

  11. The number of study dropouts due to serious, unanticipated treatment emergent adverse events

    The dropouts will be presented by treatment arm from baseline.

    Time frame: up to 12 weeks

07

Study locations

6 sites
  • UCSD Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
08

References and documents

Publications

  • Granucci EJ, Griciuc A, Mueller KA, Mills AN, Le H, Dios AM, McGinty D, Pereira J, Elmaleh D, Berry JD, Paganoni S, Cudkowicz ME, Tanzi RE, Sadri-Vakili G. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9(1):17728. doi: 10.1038/s41598-019-53982-w. PubMed 31776380 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Oct 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 11, 2020
StartActual
Sep 8, 2020
Primary completionActual
Oct 1, 2021
CompletionActual
Oct 1, 2021
Last update
Nov 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04428775
Lead sponsor
AZTherapies, Inc.
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Sep 8, 2020
Primary completion
Oct 1, 2021
Completion
Oct 1, 2021
Last update
Nov 8, 2021

Study contacts

David R. Elmaleh, PhD
study director · AZTherapies, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cromolyn

Start the discussion